Does Blue Cross Blue Shield of Michigan Cover Saxenda?

What Saxenda Is and Why Coverage Is Complicated

Saxenda is a once-daily injectable GLP-1 receptor agonist containing liraglutide 3 mg. The FDA approved it in 2014 specifically for chronic weight management, making it distinct from its lower-dose sibling Victoza (liraglutide 1.2-1.8 mg), which carries a diabetes indication. Saxenda's full prescribing information is available on the FDA accessdata portal. [1]

Coverage is complicated for one structural reason: the Affordable Care Act mandates coverage for preventive services but does not require insurers to cover prescription obesity treatments. That gap means each insurer writes its own obesity drug policy. BCBSM is no exception.

The FDA Label Criteria That Insurers Mirror

The FDA approved Saxenda for adults with a BMI ≥30 kg/m², or a BMI ≥27 kg/m² combined with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. The FDA approval package is indexed at PubMed through related clinical pharmacology reviews. [2] BCBSM prior authorization criteria track these thresholds almost exactly, so verifying your BMI against both cutoffs before submitting a claim is the first practical step.

Why Saxenda Lands on a High-Cost Tier

Specialty-tier placement reflects two things: list price and utilization management goals. At a retail price of roughly $1,500 per month, Saxenda competes with other brand-name obesity agents. Insurers place it on Tier 4 or Tier 5 specifically to require prior authorization and, in many cases, step therapy through lower-cost interventions first. The CMS national drug pricing data confirms that GLP-1 obesity agents represent some of the fastest-growing specialty pharmacy spend in the country. [3]

BCBSM Commercial Plan Coverage: What the Evidence Shows

BCBSM commercial plans sold to Michigan employers vary by employer group contract. Not all plans include obesity drug benefits at all. Some self-insured employers opt out of obesity medication coverage entirely under ERISA rules, regardless of what the standard BCBSM formulary says.

Plans That Typically Include Saxenda

PPO and HMO products sold directly by BCBSM to small and large group employers most commonly list Saxenda on the specialty tier with prior authorization required. Individual marketplace plans (ACA exchange) through BCBSM have historically been less consistent about obesity drug coverage, though this has shifted somewhat after the Treat and Reduce Obesity Act advocacy pushed more plans to add weight-management benefits.

A 2021 analysis in Obesity journal (PMID 34587354) found that fewer than 40% of U.S. Commercial insurance plans covered at least one anti-obesity medication without step therapy restrictions. [4] That figure has improved modestly, but many BCBSM members still face significant barriers.

Plans That Commonly Exclude Saxenda

Self-funded employer plans administered by BCBSM (where the employer, not BCBSM, bears the financial risk) may exclude anti-obesity medications entirely. Members on these plans will see Saxenda listed as "not covered" on their Explanation of Benefits, and prior authorization submissions are denied at the eligibility level before clinical review even begins. Calling the number on the back of your BCBSM card and asking specifically whether your plan has an obesity medication benefit is the fastest way to confirm this.

Medicare Advantage and Saxenda Under BCBSM

Traditional Medicare Part D has historically excluded coverage for weight-loss drugs under the Social Security Act's exclusion category. That exclusion still applies as of early 2025 for most stand-alone Part D plans. CMS guidance on the Part D drug exclusion categories is explicit on this point. [5]

The Inflation Reduction Act and Future Coverage

The Inflation Reduction Act did not remove the obesity drug exclusion from Part D, but the TREAT Act and related legislative efforts may change this. [6] A small number of BCBSM Medicare Advantage plans have added supplemental obesity drug benefits using rebate dollars, but this is plan-specific. Checking the Annual Notice of Change document your BCBSM Medicare Advantage plan mails each September is the only reliable way to confirm whether Saxenda appears on the plan's formulary for the coming benefit year.

Medicare Advantage Coverage Rates for GLP-1 Obesity Agents

A 2023 KFF analysis found that only about 1 in 4 Medicare Advantage prescription drug plans covered at least one GLP-1 obesity agent. The peer-reviewed field of GLP-1 coverage gaps is documented at PMID 37490882. [6] BCBSM Medicare Advantage plans mirror this national pattern.

Prior Authorization Requirements for Saxenda on BCBSM Plans

Prior authorization is the central hurdle. Submitting the request without the right documentation is the single most common reason for denial.

Clinical Documentation Your Prescriber Must Submit

BCBSM prior authorization for Saxenda typically requires:

• Current height, weight, and calculated BMI meeting the FDA threshold
• Diagnosis code for obesity (ICD-10: E66.01 for morbid obesity, E66.09 for other obesity, or Z68.xx for BMI status)
• Documentation of at least one weight-related comorbidity if BMI is ≥27 but <30
• A note confirming the patient has participated in a structured diet and exercise program, usually for 3-6 months, without achieving target weight loss
• Confirmation that the prescriber is a licensed physician, NP, or PA with prescribing authority in Michigan
• Lab work supporting comorbidity claims (e.g., fasting glucose, HbA1c, lipid panel, blood pressure readings)

The American Association of Clinical Endocrinology 2022 Obesity Clinical Practice Guidelines specifically recommend pharmacotherapy as an adjunct to lifestyle intervention when BMI thresholds are met, which provides direct language your prescriber can quote in the prior authorization letter. [7]

Step Therapy: What You May Have to Try First

Many BCBSM plans require step therapy, meaning you must document failure of a prior intervention before Saxenda is approved. Depending on the plan, that step may involve:

1. A documented 12-16-week structured lifestyle program (e.g., an intensive behavioral therapy program billed under CPT 99401-99404)
2. A trial of phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) if those agents appear on the formulary at a lower tier
3. In some plans, a trial of orlistat (Alli/Xenical), although this is less common given its tolerability profile

The AACE/ACE 2016 Obesity Algorithm states that pharmacotherapy choice should be individualized based on comorbidities and contraindications, which your prescriber can use to argue against a step therapy requirement when a specific prior agent is medically contraindicated. [8]

How Long Prior Authorization Approval Lasts

BCBSM prior authorizations for Saxenda are typically granted for 12 months. At renewal, most plans require documentation of clinically meaningful weight loss, generally defined as at least 4-5% body weight reduction from baseline at the 12-week mark (mirroring the FDA label's own responder criterion). FDA Saxenda label section 5.3 states that patients who do not achieve at least 4% weight loss by 16 weeks are unlikely to achieve meaningful long-term benefit and should discontinue. [1]

The Clinical Evidence That Supports Your Prescriber's PA Letter

Knowing the trial data helps your prescriber write a stronger prior authorization narrative. Weak PA letters cite "the patient needs to lose weight." Strong letters cite specific outcomes from named trials.

SCALE Obesity and Prediabetes Trial

The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI ≥30 (or ≥27 with dyslipidemia or hypertension) to liraglutide 3 mg or placebo for 56 weeks alongside a reduced-calorie diet and exercise. Published in the New England Journal of Medicine, PMID 25905203. [9] Liraglutide 3 mg produced a mean weight loss of 8.0% vs. 2.6% for placebo (P<0.001). Sixty-three percent of liraglutide patients lost at least 5% of body weight compared to 27% on placebo. [9]

SCALE Diabetes Trial

The SCALE Diabetes trial (N=846) tested liraglutide 3 mg in adults with type 2 diabetes and BMI ≥27. Published in Diabetes Care, accessible via PubMed PMID 26343186. [10] Mean weight loss was 6.0% with liraglutide 3 mg vs. 2.0% with placebo (P<0.001) at 56 weeks, with concurrent HbA1c reductions of 1.3 percentage points. [10] If your comorbidity is type 2 diabetes, citing this trial specifically is more persuasive than the general obesity trial.

Cardiovascular Safety Data

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg (Victoza) in patients with type 2 diabetes at high cardiovascular risk and showed a 13% relative reduction in major adverse cardiovascular events vs. Placebo. NEJM publication, PMID 27295427. [11] While this was the diabetes dose rather than the 3 mg obesity dose, insurers and reviewers recognize liraglutide's cardiovascular safety profile, and citing LEADER in a PA letter for a patient with documented cardiovascular risk factors is appropriate. The FDA's cardiovascular outcome trial guidance adds context for reviewers evaluating safety concerns. [12]

What to Do When BCBSM Denies Saxenda Coverage

Denial is not the end of the process. Michigan law and federal ACA rules give you specific appeal rights.

Level 1 Internal Appeal

File within 180 days of the denial notice. Your prescriber submits a letter of medical necessity that directly addresses the denial reason listed in the Explanation of Benefits. If the denial cited "not medically necessary," the letter should cite SCALE trial outcomes, AACE guidelines [7], and the patient's specific comorbidities with lab values.

Level 2 External Appeal

If the internal appeal fails, Michigan's Department of Insurance and Financial Services (DIFS) offers an Independent Medical Review process. An external physician reviewer, independent of BCBSM, evaluates the case. Success rates in independent review for specialty medications vary, but documenting every clinical touchpoint strengthens the record.

Exception Requests for Step Therapy

Michigan passed the Step Therapy Reform Act (Public Act 352 of 2018). Under this law, a prescriber can request a step therapy exception if the required prior drug is clinically contraindicated, previously failed, or likely to cause harm. The Michigan DIFS step therapy overview outlines the process. Prescribers should file this simultaneously with the prior authorization to save time.

Cost-Reduction Strategies When Coverage Is Denied or Incomplete

Novo Nordisk Saxenda Savings Card

Novo Nordisk offers a savings card for commercially insured patients. Eligible patients pay as little as $25 per 30-day supply, with Novo Nordisk covering up to $200 per fill. The program is not available to Medicare, Medicaid, or uninsured patients. Novo Nordisk's patient assistance programs are documented alongside FDA prescribing information at the FDA label page. [1]

Novo Nordisk Patient Assistance Program

Uninsured or underinsured patients with household income below 400% of the federal poverty level may qualify for Saxenda at no cost through the Novo Nordisk Patient Assistance Program. Applications require income verification and a prescriber signature.

340B Covered Entities in Michigan

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities in Michigan purchase medications at significantly reduced prices and may be able to dispense Saxenda to qualifying low-income patients at minimal cost. The HRSA 340B drug pricing program maintains a list of covered entities by zip code. [13]

Switching to a Covered Alternative

If Saxenda is denied and appeals fail, Wegovy (semaglutide 2.4 mg weekly) or Zepbound (tirzepatide 5-15 mg weekly) may be covered on BCBSM formularies under different criteria. STEP-1 (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks vs. 2.4% placebo. NEJM publication PMID 33567185. [14] The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg producing 20.9% mean weight loss at 72 weeks vs. 3.1% placebo. NEJM publication PMID 35658024. [15] Switching to a covered agent with stronger efficacy data can sometimes be the path of least resistance.

How Prescribers Can Optimize the Prior Authorization Submission

The difference between approval and denial often comes down to how the PA request is written, not the patient's clinical profile.

Specific Language That Mirrors Guideline Criteria

"The patient has a documented BMI of [X] kg/m² with [comorbidity]. Per the 2022 AACE Obesity Clinical Practice Guidelines (Endocrine Practice 2022, PMID 35931462), pharmacotherapy with a GLP-1 receptor agonist is a recommended adjunct to intensive behavioral intervention at this BMI with this comorbidity profile. The patient completed a structured 12-week dietary intervention with [provider name] achieving less than 3% body weight reduction, meeting the definition of inadequate lifestyle response." [7]

Documenting Contraindications to Step Therapy Agents

If the plan requires a trial of phentermine/topiramate first, note any contraindications: uncontrolled hypertension (phentermine), glaucoma (topiramate), prior renal stones (topiramate), or patient-reported intolerance to stimulant medications. The FDA prescribing information for Qsymia lists contraindications your prescriber can reference directly. [16]

Requesting Peer-to-Peer Review

If the initial PA is denied, most BCBSM plans allow the prescribing physician to request a peer-to-peer phone review with the insurer's medical director. This call typically lasts 10-15 minutes. Coming prepared with BMI, lab values, comorbidities, prior treatment history, and two or three specific trial citations (SCALE [9], AACE guidelines [7]) significantly improves the conversion rate of these calls.

Adolescent Coverage: BCBSM and Saxenda for Ages 12 to 17

The FDA expanded Saxenda's indication in December 2020 to include adolescents aged 12-17 with a body weight above 60 kg and obesity as defined by pediatric BMI-for-age criteria. FDA adolescent approval summary at PMID 35196429. [17] BCBSM prior authorization for this age group typically requires additional documentation:

• Pediatric endocrinologist or obesity medicine specialist involvement
• Confirmation that intensive behavioral interventions have been attempted
• Baseline cardiovascular and metabolic workup
• Parental/guardian consent documentation

The SCALE Teens trial (N=251) showed liraglutide 3 mg produced 5.8 kg greater weight loss than placebo over 56 weeks in adolescents, with 43.3% achieving at least 5% BMI reduction vs. 18.7% on placebo. New England Journal of Medicine, PMID 35196429. [17]